Takafuji E T, Gaydos J C, Allen R G, Top F H
J Infect Dis. 1979 Jul;140(1):48-53. doi: 10.1093/infdis/140.1.48.
The safety of and the immune response to simultaneous administration of live, enteric-coated adenovirus type 4 (ADV-4), type 7 (ADV-7), and type 21 (ADV-21) vaccines were studied. Volunteers (476 men), randomly assigned to four study groups, received three vaccines (ADV-4, ADV-7, and ADV-21), two vaccines (ADV-4 and ADV-7), one vaccine (ADV-21), or no vaccine (placebo). Subjects were observed for three weeks, and no side effects due to vaccination occured. The percentages of susceptible subjects (those entering the study with a neutralizing antibody titer of less than 1:2 to each vaccine virus received) who seroconverted to ADV-4 were similar in both groups that received ADV-4 vaccine (78% of 77 subjects and 74% of 76). However, in the group that received three vaccines, only 62% of 77 subjects seroconverted to ADV-7, compared with 79% of 76 in the group that received two vaccines (P less than 0.05). Only 58% of 77 subjects in the three-vaccine group seroconverted to ADV-21, compared with 69% of 59 in the group that received one vaccine (P greater than 0.1).
对同时接种活的肠溶衣腺病毒4型（ADV - 4）、7型（ADV - 7）和21型（ADV - 21）疫苗的安全性及免疫反应进行了研究。志愿者（476名男性）被随机分配到四个研究组，分别接受三种疫苗（ADV - 4、ADV - 7和ADV - 21）、两种疫苗（ADV - 4和ADV - 7）、一种疫苗（ADV - 21）或不接种疫苗（安慰剂）。对受试者观察了三周，未出现因接种疫苗导致的副作用。在接受ADV - 4疫苗的两组中，对ADV - 4发生血清转化的易感受试者（即入组时对所接种的每种疫苗病毒的中和抗体效价低于1:2的受试者）百分比相似（77名受试者中的78%和76名受试者中的74%）。然而，在接受三种疫苗的组中，77名受试者中只有62%对ADV - 7发生血清转化，而接受两种疫苗的组中76名受试者的这一比例为79%（P小于0.05）。在接受三种疫苗的组中，77名受试者中只有58%对ADV - 21发生血清转化，而接受一种疫苗的组中59名受试者的这一比例为69%（P大于0.1）。
